Skip to main content

Early data show promise for the FGFR inhibitor rogaratinib

Pills in hand

The FGFR inhibitor rogaratinib is well tolerated and clinically active in patients with various tumor types selected for treatment on the basis of FGFR mRNA overexpression, phase I study data show.


Support for switching between upadacitinib and adalimumab in RA patients

Rheumatoid arthritis medication

48-week results from the SELECT-COMPARE study indicate that upadacitinib has sustained efficacy in patients with rheumatoid arthritis, and that individuals with an inadequate response to upadacitinib or adalimumab may benefit from switching to the alternate therapy.


Monocyte counts could predict IPF outcome


Elevated monocyte counts are associated with poor outcomes among patients with idiopathic pulmonary fibrosis, suggest study findings published in The Lancet Respiratory Medicine.

Headlines from across medwireNews

21-08-2019 | Rheumatology | News | Article

Upadacitinib gains FDA approval for RA

Click through for more information on this approval

21-08-2019 | Rheumatology | News | Article

EULAR updates vaccination guidance for patients with rheumatic diseases

EULAR has developed up-to-date guidelines for the use of vaccinations in patients with rheumatic diseases, based on a systematic literature review and expert opinion.

21-08-2019 | Oncology | News | Article

Long-term benefit of nivolumab plus ipilimumab shown in advanced RCC

Patients with previously untreated advanced renal cell carcinoma derive greater long-term survival benefits from nivolumab plus ipilimumab than from sunitinib, according to the latest results from the phase III CheckMate 214 trial.

21-08-2019 | Diabetes | News | Article

Lifestyle counseling linked with improved diabetes outcomes

Regularly counseling patients with diabetes about their lifestyles during routine care could benefit their long-term clinical outcomes, US research suggests, possibly due to improved blood glucose control.

20-08-2019 | Oncology | News | Article

Study supports use of fosnetupitant in combination with palonosetron for CINV

A phase II trial shows that the intravenous prodrug fosnetupitant in combination with palonosetron reduces chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.

20-08-2019 | Diabetes | News | Article

Succinate levels may predict diabetes remission after bariatric surgery

Individuals with lower preoperative levels of serum succinate are more likely to achieve remission of type 2 diabetes after bariatric surgery than those with higher levels of the metabolite, study results suggest.

medwireNews is an established provider of authoritative, timely and independent medical news. We value your feedback and encourage you to contact us to make your preferred medical news resource.

Meet the team

Image Credits